Latest News & Features
Big Pharma
Leaving the EU without a deal in place could “irreparably” harm the UK’s National Health Service and lead to delays in new products being bought to market in the country, according to the British Medical Association. 3 September 2019
Biotechnology
An alliance of companies that use gene-editing technologies has released a bioethical framework, as controversy over gene-editing continues. 3 September 2019
Big Pharma
Nicole Jadeja, the former co-head of life sciences at Fieldfisher, has joined Pinsent Masons as a partner in its London office. 3 September 2019
Genetics
The World Health Organization has launched a global registry to track research on human genome editing. 3 September 2019
Generics
The US Court of Appeals for the Federal Circuit has ruled that claims in an Allergan patent detailing the results of a glaucoma treatment are material to its patentability, after an unsuccessful invalidation appeal brought by Sandoz. 30 August 2019
Generics
The Delhi High Court has cleared the way for a generic version of Novartis’ small-cell lung cancer drug Ceritinib, after the Swiss pharmaceutical company’s patent was revoked. 29 August 2019
Americas
A US judge yesterday, August 28 ruled in favour of Sanofi and Regeneron in the pharmaceutical companies’ long-running patent dispute with Amgen over the cholesterol drug Praluent. 29 August 2019
Big Pharma
The US Patent Trial and Appeal Board has instituted an inter partes review into a patent covering an opioid overdose treatment owned by Nalox-1 Pharmaceuticals. 29 August 2019
Biotechnology
For all the importance of the role of government and private sector bodies in the realisation of precision medicine, it’s important not to lose sight of the interests and concerns of those precision medicine intends to treat—the patients and public at large, write Daniel Lim and Anna Jackson of Kirkland & Ellis. 29 August 2019
Big Pharma
Biotech company Ionis Pharmaceuticals is to license its antisense medicines, used to treat people with chronic hepatitis B, to GlaxoSmithKline. 28 August 2019